|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adams SV, Newcomb PA and Shustov AR:
Racial patterns of peripheral T-cell lymphoma incidence and
survival in the United States. J Clin Oncol. 34:963–971. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sant M, Allemani C, Tereanu C, De Angelis
R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti
A, Lutz JM, et al: Incidence of hematologic malignancies in Europe
by morphologic subtype: Results of the HAEMACARE project. Blood.
116:3724–3734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi Y: Current status and progress of
lymphoma management in China. Int J Hematol. 107:405–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
d'Amore F, Gaulard P, Trümper L, Corradini
P, Kim WS, Specht L, Bjerregaard Pedersen M and Ladetto M; ESMO
Guidelines Committee, : Peripheral T-cell lymphomas: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26 (Suppl 5):v108–v115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weisenburger DD, Savage KJ, Harris NL,
Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura
S, Nathwani B, et al: Peripheral T-cell lymphoma, not otherwise
specified: A report of 340 cases from the international peripheral
T-cell lymphoma project. Blood. 117:3402–3408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oluwasanjo A, Kartan S, Johnson W,
Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J and Porcu P:
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).
Cancer Treat Res. 176:83–98. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pileri SA, Tabanelli V, Fiori S, Calleri
A, Melle F, Motta G, Lorenzini D, Tarella C and Derenzini E:
Peripheral T-cell lymphoma, not otherwise specified: Clinical
manifestations, diagnosis, and future treatment. Cancers (Basel).
13:45352021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorial M, Aniagboso K, Buttermore E, Lei
M, Kendall E, Nasto K, Koh MJ, Han JX, Boussi L, Malpica L, et al:
Early time-to-relapse as a predictor of survival in mature
T-cell/NK-cell lymphomas: Results from the PETAL consortium. Blood.
146 (Suppl 1):S8892025. View Article : Google Scholar
|
|
10
|
Broccoli A and Zinzani PL: Peripheral
T-cell lymphoma, not otherwise specified. Blood. 129:1103–1112.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee C and An Y: Deciphering the genetic
complexity of classical hodgkin lymphoma: Insights and effective
strategies. Curr Genomics. 25:334–342. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lyu G and Li D: PLEKHG7 expression: A
biomarker for prognosis and targeted therapy in diffuse large
B-cell lymphoma. Protein Pept Lett. 32:657–666. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of
tumours of haematopoietic and lymphoid tissues. International
agency for research on cancer Lyon; France: 2017
|
|
14
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
15
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–656. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project, . A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horwitz SM, Ansell S, Ai WZ, Barnes J,
Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, et al:
NCCN Clinical Practice Guidelines in Oncology. T-Cell Lymphomas,
Version 2.2022. J Natl Compr Canc Netw. 20:285–308. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang QY, Feng JF, Wang HQ, Huang HQ,
Zhang HL, Li XC, Gao YY, Song YP, Li ZM, et al: China Anti-Cancer
Association (CACA) guidelines for holistic integrative management
of lymphoma (version 2022). Holist Integ Oncol. 2:412023.
View Article : Google Scholar
|
|
19
|
Gallamini A, Stelitano C, Calvi R, Bellei
M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E,
Iannitto E, et al: Peripheral T-cell lymphoma unspecified (PTCL-U):
A new prognostic model from a retrospective multicentric clinical
study. Blood. 103:2474–2479. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian
Leukaemia; Lymphoma Group and Eastern Cooperative Oncology Group, ;
et al: Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano
classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Common Terminology Criteria for Adverse
Events (CTCAE) Version 5.0. U.S. Department of Health and Human
Services; Washington, DC: 2017
|
|
22
|
Chen NC, Chang H, Kuo MC, Lin TL, Shih LY,
Chuang WY and Kao HW: Predictive model for treatment outcomes of
peripheral T-cell lymphoma, not otherwise specified, in Taiwanese
patients. J Formos Med Assoc. 123:188–197. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the World Health Organization classification
of haematolymphoid tumours: Myeloid and histiocytic/dendritic
neoplasms. Leukemia. 36:1703–1719. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Davis O, Truong D, Day S, Pandey M,
Ibrahimi S, Khawandanah M, Holter-Chakrabarty J, Asch A and
Al-Juhaishi T: Impact of primary organ site of involvement by
peripheral T-cell lymphoma not otherwise specified on survival.
Cancer Med. 12:21770–21778. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicolae A, Bouilly J, Lara D, Fataccioli
V, Lemonnier F, Drieux F, Parrens M, Robe C, Poullot E, Bisig B, et
al: Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in
the clinical setting of immunodysregulation and is associated with
recurrent epigenetic alterations. Mod Pathol. 35:1126–1136. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herek TA, Bouska A, Lone W, Sharma S,
Amador C, Heavican TB, Li Y, Wei Q, Jochum D, Greiner TC, et al:
DNMT3A mutations define a unique biological and prognostic subgroup
associated with cytotoxic T cells in PTCL-NOS. Blood.
140:1278–1290. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iqbal J, Wright G, Wang C, Rosenwald A,
Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox
RA, et al: Gene expression signatures delineate biological and
prognostic subgroups in peripheral T-cell lymphoma. Blood.
123:2915–2923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amador C, Greiner TC, Heavican TB, Smith
LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S,
et al: Reproducing the molecular subclassification of peripheral
T-cell lymphoma-NOS by immunohistochemistry. Blood. 134:2159–2170.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asano N, Suzuki R, Kagami Y, Ishida F,
Kitamura K, Fukutani H, Morishima Y, Takeuchi K and Nakamura S:
Clinicopathologic and prognostic significance of cytotoxic molecule
expression in nodal peripheral T-cell lymphoma, unspecified. Am J
Surg Pathol. 29:1284–1293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kato S, Takahashi E, Asano N, Tanaka T,
Megahed N, Kinoshita T and Nakamura S: Nodal cytotoxic molecule
(CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell
lymphoma (PTCL): A clinicopathological study of 26 cases.
Histopathology. 61:186–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Went P, Agostinelli C, Gallamini A,
Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T,
Paulli M, et al: Marker expression in peripheral T-cell lymphoma: A
proposed clinical-pathologic prognostic score. J Clin Oncol.
24:2472–2479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gutiérrez-García G, García-Herrera A,
Cardesa T, Martínez A, Villamor N, Ghita G, Martínez-Trillos A,
Colomo L, Setoain X, Rodríguez S, et al: Comparison of four
prognostic scores in peripheral T-cell lymphoma. Ann Oncol.
22:397–404. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Shi J, Xie H, Liu X, Ruan G, Lin
S, Ge Y, Liu C, Chen Y, Zheng X, et al: Superiority of
CRP-albumin-lymphocyte index as a prognostic biomarker for patients
with gastric cancer. Nutrition. 116:1121912023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X, Meng QH, Ye Y, Hildebrandt MAT, Gu
J and Wu X: Prognostic significance of pretreatment serum levels of
albumin, LDH and total bilirubin in patients with non-metastatic
breast cancer. Carcinogenesis. 36:243–248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo Y, Wei L, Patel SH, Lopez G, Grogan M,
Li M, Haddad T, Johns A, Ganesan LP, Yang Y, et al: Serum albumin:
Early prognostic marker of benefit for immune checkpoint inhibitor
monotherapy but not chemoimmunotherapy. Clin Lung Cancer.
23:345–355. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Federico M, Bellei M, Marcheselli L,
Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME,
Horwitz S, et al: Peripheral T cell lymphoma, not otherwise
specified (PTCL-NOS). A new prognostic model developed by the
international T cell project network. Br J Haematol. 181:760–769.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaito S, Kanemasa Y, Sasaki Y, Okuya T,
Yamaguchi T, Funasaka C, Shimoyama T, Omuro Y, Hishima T and Maeda
Y: A new prognostic score comprising lactate dehydrogenase, albumin
and neutrophil to lymphocyte ratio to predict sensitivity to
first-line chemotherapy in patients with peripheral T-cell
lymphomas. Int J Hematol. 107:451–459. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen H, Tao Y, Zhou Y, Liu P, Yang J, He
X, Zhou S, Qin Y, Song Y, Gui L, et al: The clinical features,
treatment, and prognostic factors for peripheral T-cell lymphomas:
A single-institution analysis of 240 Chinese patients. Asia Pac J
Clin Oncol. 19:e202–e214. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shen HR, Tang J, Li WY, Liang JH, Li Y, Wu
JZ, Wang L, Li JY, Gao R, Yin H and Xu W: 25-Hydroxy vitamin D
deficiency is an inferior predictor of peripheral T-cell lymphomas.
Ann Hematol. 103:565–574. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Raj SS, Fei T, Fried S, Ip A, Fein JA,
Leslie LA, Alarcon Tomas A, Leithner D, Peled JU, Corona M, et al:
An inflammatory biomarker signature of response to CAR-T cell
therapy in non-Hodgkin lymphoma. Nat Med. 31:1183–1194. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu F, Wang KB and Rui L: STAT3 activation
and oncogenesis in lymphoma. Cancers (Basel). 12:192019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jaeger A, Gambheer SMM, Sun X, Chernyakov
D, Skorobohatko O, Mack T, Kissel S, Pfeifer D, Zeiser R, Fisch P,
et al: Activated granulocytes and inflammatory cytokine signaling
drive T-cell lymphoma progression and disease symptoms. Blood.
141:2824–2840. 2023.PubMed/NCBI
|
|
43
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project, : International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ellin F, Landström J, Jerkeman M and
Relander T: Real-world data on prognostic factors and treatment in
peripheral T-cell lymphomas: A study from the Swedish lymphoma
registry. Blood. 124:1570–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai
J, Zou Q, Tian X, Xia Y, Liu P, et al: Comparison of chemotherapy
combined with chidamide versus chemotherapy in the frontline
treatment for peripheral T-cell lymphoma. Front Immunol.
13:8351032022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Horwitz S, O'Connor OA, Pro B, Illidge T,
Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F,
Domingo-Domenech E, et al: Brentuximab vedotin with chemotherapy
for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global,
double-blind, randomised, phase 3 trial. Lancet. 393:229–240. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sureda A, García-Sanz R, Domingo-Domenech
E, Capote FJ, Gutiérrez A, Rodriguez A, Aguiar D, Giraldo P,
Infante MS, López-Jiménez J, et al: Retreatment with brentuximab
vedotin in patients with relapsed/refractory CD30+ malignancies: A
retrospective medical chart review study in Spain-The BELIEVE
study. Cancers (Basel). 17:11372025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brink M, Meeuwes FO, van der Poel MWM,
Kersten MJ, Wondergem M, Mutsaers PGNJ, Böhmer LH, Woei-A-Jin FSH,
Visser O, Oostvogels R, et al: Impact of etoposide and ASCT on
survival among patients aged <65 years with stage II to IV PTCL:
A population-based cohort study. Blood. 140:1009–1019. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Park SI, Horwitz SM, Foss FM, Pinter-Brown
LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C,
et al: The role of autologous stem cell transplantation in patients
with nodal peripheral T-cell lymphomas in first complete remission:
Report from COMPLETE, a prospective, multicenter cohort study.
Cancer. 125:1507–1517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meeuwes FO, Serroukh YIM, van der Poel
MWM, Plattel WJ and Nijland M: Relapsed and refractory peripheral
T-cell lymphoma; treatment, challenges and future perspectives.
Leuk Lymphoma. 66:2341–2356. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qi F, Dong M, He X, Li Y, Wang W, Liu P,
Yang J, Gui L, Zhang C, Yang S, et al: Gemcitabine, dexamethasone,
and cisplatin (GDP) as salvage chemotherapy for patients with
relapsed or refractory peripheral T cell lymphoma-not otherwise
specified. Ann Hematol. 96:245–251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mikesch JH, Kuhlmann M, Demant A, Krug U,
Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr
M, et al: DexaBEAM versus ICE salvage regimen prior to autologous
transplantation for relapsed or refractory aggressive peripheral T
cell lymphoma: A retrospective evaluation of parallel patient
cohorts of one center. Ann Hematol. 92:1041–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bachy E, Camus V, Thieblemont C, Sibon D,
Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, et al:
Romidepsin Plus CHOP Versus CHOP in Patients With Previously
Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase
III Study (Conducted by LYSA). J Clin Oncol. 40:242–251. 2022.
View Article : Google Scholar : PubMed/NCBI
|
